CAR-T cell therapy research
Open access
Peer reviewed
Scollr summary
What this paper is about
It is found that CD5 inhibits CAR T cell activation and that knockout (KO) of CD5 using CRISPR-Cas9 enhances the antitumor effect of CAR T cells in multiple hematological and solid cancer models, indicating that CD5 is a critical inhibitor of T cell function and a potential clinical target for enhancing T cell therapies.
Full abstract
Read the full abstract
Most patients treated with US Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T cells eventually experience disease progression. Furthermore, CAR T cells have not been curative against solid cancers and several hematological malignancies such as T cell lymphomas, which have very poor prognoses. One of the main barriers to the clinical success of adoptive T cell immunotherapies is CAR T cell dysfunction and lack of expansion and/or persistence after infusion. In this study, we found that CD5 inhibits CAR T cell activation and that knockout (KO) of CD5 using CRISPR-Cas9 enhances the antitumor effect of CAR T cells in multiple hematological and solid cancer models. Mechanistically, CD5 KO drives increased T cell effector function with enhanced cytotoxicity, in vivo expansion, and persistence, without apparent toxicity in preclinical models. These findings indicate that CD5 is a critical inhibitor of T cell function and a potential clinical target for enhancing T cell therapies.
Direct answer
What can I do from this paper page?
Use this page to scan "CD5 deletion enhances the antitumor activity of adoptive T cell therapies" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow CAR-T cell therapy research, save the paper, or map adjacent work.
Research areas
Follow related topics
Citation
BibTeX
@article{Chun2024deletion,
title = {CD5 deletion enhances the antitumor activity of adoptive T cell therapies},
author = {Inkook Chun and Ruchi P. Patel and Guido Ghilardi and Yunlin Zhang and Yi‐Hao Chiang and Wei Xie and Puneeth Guruprasad and Ki Hyun Kim and Mathew G. Angelos and Raymone Pajarillo and Seok Jae Hong and Yong Gu Lee and Olga Shestova and Carolyn E. Shaw and Ivan Cohen and Aasha Gupta and Trang Vu and Dean Qian and Steven Yang and Aditya Nimmagadda and Adam E. Snook and Nicholas A. Siciliano and Antonia Rotolo and Arati A. Inamdar and Jaryse Harris and Ositadimma Ugwuanyi and Michael Wang and Alberto Carturan and Luca Paruzzo and Linhui Chen and Hatcher J. Ballard and Tatiana Blanchard and Chong Xu and Mohamed Abdel‐Mohsen and Khatuna Gabunia and Maria Wysocka and Gerald P. Linette and Beatriz M. Carreno and David M. Barrett and David T. Teachey and Avery D. Posey and Daniel J. Powell and C Sauter and Stefano Pileri and Vinodh Pillai and John Scholler and Alain H. Rook and Stephen J. Schuster and Stefan K. Barta and Patrizia Porazzi and Marco Ruella},
journal = {Science Immunology},
year = {2024},
doi = {10.1126/sciimmunol.adn6509},
url = {https://doi.org/10.1126/sciimmunol.adn6509}
}FAQ
Using this paper in a discovery workflow
How do I find related work for this paper?
Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.
How can I keep up with new CAR-T cell therapy research papers?
Follow CAR-T cell therapy research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.
Can I cite this paper from this page?
This page includes a static BibTeX block for CD5 deletion enhances the antitumor activity of adoptive T cell therapies. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.
Follow this research in Scollr
Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.
Get the app